These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 33413032)
1. Identification of potential SARS-CoV-2 M Sobhia ME; Ghosh K; Sivangula S; Kumar S; Singh H J Biomol Struct Dyn; 2022 Jul; 40(11):5079-5089. PubMed ID: 33413032 [TBL] [Abstract][Full Text] [Related]
2. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
3. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy. Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346 [TBL] [Abstract][Full Text] [Related]
4. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682 [TBL] [Abstract][Full Text] [Related]
5. Exploring epigenetic drugs as potential inhibitors of SARS-CoV-2 main protease: a docking and MD simulation study. Uzuner U; Akkus E; Kocak A; Çelik Uzuner S J Biomol Struct Dyn; 2024 Aug; 42(13):6892-6903. PubMed ID: 37458994 [TBL] [Abstract][Full Text] [Related]
6. Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M Rao P; Shukla A; Parmar P; Rawal RM; Patel B; Saraf M; Goswami D Biophys Chem; 2020 Sep; 264():106425. PubMed ID: 32663708 [TBL] [Abstract][Full Text] [Related]
7. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease. Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983 [TBL] [Abstract][Full Text] [Related]
8. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection. Martorana A; Gentile C; Lauria A Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574 [TBL] [Abstract][Full Text] [Related]
9. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies. Roy R; Sk MF; Jonniya NA; Poddar S; Kar P J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642 [TBL] [Abstract][Full Text] [Related]
12. Investigation of bio-active Amaryllidaceae alkaloidal small molecules as putative SARS-CoV-2 main protease and host TMPRSS2 inhibitors: interpretation by Bhowmick S; Mistri TK; Khan MR; Patil PC; Busquets R; Ashif Ikbal AM; Choudhury A; Roy DK; Palit P; Saha A J Biomol Struct Dyn; 2024 Sep; 42(14):7107-7127. PubMed ID: 37482789 [TBL] [Abstract][Full Text] [Related]
13. Investigating the structure-activity relationship of marine polycyclic batzelladine alkaloids as promising inhibitors for SARS-CoV-2 main protease (M Elgohary AM; Elfiky AA; Pereira F; Abd El-Aziz TM; Sobeh M; Arafa RK; El-Demerdash A Comput Biol Med; 2022 Aug; 147():105738. PubMed ID: 35777088 [TBL] [Abstract][Full Text] [Related]
14. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors. Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303 [TBL] [Abstract][Full Text] [Related]
15. On the search for COVID-19 therapeutics: identification of potential SARS-CoV-2 main protease inhibitors by virtual screening, pharmacophore modeling and molecular dynamics. Hassan A; Arafa RK J Biomol Struct Dyn; 2022 Oct; 40(17):7815-7828. PubMed ID: 33749545 [TBL] [Abstract][Full Text] [Related]
16. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation. Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783 [TBL] [Abstract][Full Text] [Related]
17. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors. Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388 [TBL] [Abstract][Full Text] [Related]
18. Binding and inhibitory effect of ravidasvir on 3CL Bera K J Biomol Struct Dyn; 2022 Oct; 40(16):7303-7310. PubMed ID: 33682639 [TBL] [Abstract][Full Text] [Related]
19. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus. Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A Molecules; 2020 May; 25(11):. PubMed ID: 32485894 [TBL] [Abstract][Full Text] [Related]
20. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study. Ancy I; Sivanandam M; Kumaradhas P J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]